The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

Pharmaceutical
Herbal
API / Bulk Drugs
Personal care
International

History and milestone

Past Initiatives

First Indian to produce Doxycycline Inj.
First Indian company to make Liquid Oxytetracycline Inj.
Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
First Company to launch Boswellia Serrata tablets
Pioneer in developing Kid tablet in India
Hived off Mox and Zole to Ranbaxy

2007-2009

Initiated contract manufacturing
Commenced international exports

2010-2015

Received patents for Anidulafungin and Tigecycline lyophilized inj.
Launched Criticare division

2016

Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
Launched Ferticare and Criticare Life divisions

2017-2019

Received patents for Rifabutin and Micafunginlyophilized inj.
Exported Vancomycin lyophilized Inj. to Germany
Manufacturing capacity ramped up to 31 million vials per annum
Launched Ferticare Life division

2020

Manufacturing Remdesivir for Hetero
Increased capacity to 48 million vials per annum

2022

Incorporated wholly owned subsidiary company namely ‘Gufic UK’
Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)

Open Price	286.4	Volume	2
Prev. Close	286.4

Performance